A Randomized, Double-blind Controlled Study to Determine the Effectiveness, Safety and Tolerability of Actoferon Compared to Betaferon in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)

Trial Profile

A Randomized, Double-blind Controlled Study to Determine the Effectiveness, Safety and Tolerability of Actoferon Compared to Betaferon in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Actover Pharmaceutical
  • Most Recent Events

    • 09 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top